Positive data for HDAC inhibitor - Medivir

Sweden-based Medivir AB has reported positive Phase 2 data for a recently acquired histone deacetylase (HDAC) inhibitor in a trial of patients with early-stage cutaneous T cell lymphoma (CTCL), a haematologic cancer that presents in the skin.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Sweden